Meta‐analysis results do not reflect the real safety of biologics in psoriasis*
- 23 May 2020
- journal article
- review article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 184 (3) , 415-424
Abstract
Background In systematic reviews (SR) and meta‐analyses (MA) of randomized controlled trials (RCTs) assessing treatments of psoriasis, the proportion of serious adverse events (SAEs) did not differ between treatments and placebo. Including cases of psoriasis worsening as SAEs may explain the lack of difference. This SR and MA aimed to explore this possibility. Methods Among the 140 RCTs included in the Living Network Cochrane Review (last search on May 8, 2019), we selected those comparing a biological treatment to placebo. The primary outcome was the number of SAEs in treatment and placebo arms after excluding cases of psoriasis worsening. Secondary outcomes were number of adverse events (AEs) of special interest. Results We analyzed 51 RCTs. Of these, 21 included at least one anti‐TNF‐alpha arm, 15 one anti‐IL‐17 arm, 11 one anti‐IL‐23 arm and 9 one anti‐IL‐12/23 arm. With cases of psoriasis worsening included, the risk of occurrence of SAEs between biological treatments and placebo did not differ: RR=1.09 (95% CI 0.88‐1.36). After excluding cases of psoriasis worsening, the RR became significant: RR=1.30 (95% CI 1.02‐1.65). By drug class, the RRs for anti‐TNF‐alpha were 1.68 (95% CI 1.11‐2.54; 20 out of 21 trials used), anti‐IL‐17 1.28 (95% CI 0.88‐1.85; no missing data), anti‐IL‐23 0.95 (95% CI 0.59‐1.52; no missing data), and anti‐IL‐12/23 1.18 (95% CI 0.72‐1.94; no missing data). We were unable to examine potential differences in the AEs of special interest between biologic treatments and placebo arms because of the small number of events. Conclusion On excluding cases of worsening psoriasis, the risk of occurrence of SAEs is higher in the biological than in the placebo arm. Given the rare events, we could not highlight whether this higher risk of SAEs was related to AEs of special interest. Reporting of SAEs in clinical trials has to be changed to provide more transparency through the separate reporting of disease flares leading to hospital admission and other SAEs.Keywords
This publication has 23 references indexed in Scilit:
- Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional studyBMJ Open, 2014
- Meta-Analysis of Rare Binary Adverse Event DataJournal of the American Statistical Association, 2012
- Risk of Serious Adverse Events Associated With Biologic and Nonbiologic Psoriasis Systemic TherapyArchives of Dermatology, 2012
- Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse dataStatistics in Medicine, 2010
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and ElaborationPLOS Medicine, 2009
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse dataStatistics in Medicine, 2004
- A solution to the problem of separation in logistic regressionStatistics in Medicine, 2002
- Bias reduction of maximum likelihood estimatesBiometrika, 1993
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986